Literature DB >> 26341999

Temporal release pattern of copeptin and troponin T in patients with suspected acute coronary syndrome and spontaneous acute myocardial infarction.

Anna Slagman1, Julia Searle2, Christian Müller3, Martin Möckel2.   

Abstract

BACKGROUND: The release pattern of copeptin during the initial 36 h of spontaneous acute myocardial infarction (AMI) has received relatively little investigation but may provide important information on optimal timing of diagnostic measurements.
METHODS: We investigated the release pattern of copeptin and cardiac troponin T in patients with suspected acute coronary syndrome (ACS). Blood samples were collected in the ambulance, at admission, and after 2, 4, 6, and 12-36 h. Copeptin and high-sensitivity cardiac troponin T (hs-cTnT) were measured in heparin plasma samples.
RESULTS: Of 93 patients studied, 37 (39.8%) had ST-elevation myocardial infarction (STEMI), 20 (21.5%) non-STEMI, 20 (21.5%) unstable angina pectoris (UAP), and 16 (17.2%) non-ACS diagnoses. Peak copeptin concentrations were detected during ambulance transport for NSTEMI patients [median 94.0 pmol/L, interquartile range (IQR) 53.3-302.1 pmol/L] and at admission for patients with STEMI (70.0 pmol/L, 22.0-144.8 pmol/L). In patients with AMI, copeptin decreased significantly over time (P < 0.0001). This was true for patients with STEMI (P = 0.005) and non-STEMI (P = 0.021). The diagnostic performance during ambulance transport was similar for hs-cTnT (area under the ROC curve 0.75, 95% CI 0.62-0.88) and copeptin (0.81, 0.69-0.92). In early presenters (n = 52), no patient with AMI was initially (in ambulance or at admission) negative for copeptin, resulting in an area under the ROC curve of 0.963 for ambulance values and a negative predictive value of 100%. In late presenters, the negative predictive value of copeptin was 50% in ambulance and at admission.
CONCLUSIONS: Our analysis is the first to show a consistent early increase in copeptin at first medical contact in the ambulance and a decrease to routine values within 12-36 h in patients presenting early with spontaneous AMI.
© 2015 American Association for Clinical Chemistry.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26341999     DOI: 10.1373/clinchem.2015.240580

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  10 in total

1.  Prognostic value of copeptin in patients with acute myocardial infarction treated with percutaneous coronary intervention: a prospective cohort study.

Authors:  Marta Roczek-Janowska; Michal Kacprzak; Malgorzata Dzieciol; Marzenna Zielinska; Krzysztof Chizynski
Journal:  J Thorac Dis       Date:  2021-07       Impact factor: 2.895

Review 2.  Copeptin as a Diagnostic and Prognostic Biomarker in Cardiovascular Diseases.

Authors:  Danni Mu; Jin Cheng; Ling Qiu; Xinqi Cheng
Journal:  Front Cardiovasc Med       Date:  2022-07-04

3.  Serum Copeptin Levels Predict Clinical Outcomes After Successful Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction.

Authors:  Hyun Jung Choi; Min Chul Kim; Doo Sun Sim; Young Joon Hong; Ju Han Kim; Myung Ho Jeong; Soo Hyun Kim; Myung Geun Shin; Youngkeun Ahn
Journal:  Ann Lab Med       Date:  2018-11       Impact factor: 3.464

4.  Diagnostic accuracy of adding copeptin to cardiac troponin for non-ST-elevation myocardial infarction: A systematic review and meta-analysis.

Authors:  Hyungoo Shin; Bo-Hyoung Jang; Tae Ho Lim; Juncheol Lee; Wonhee Kim; Youngsuk Cho; Chiwon Ahn; Kyu-Sun Choi
Journal:  PLoS One       Date:  2018-07-06       Impact factor: 3.240

5.  Is high-sensitivity troponin, alone or in combination with copeptin, sensitive enough for ruling out NSTEMI in very early presenters at admission? A post hoc analysis performed in emergency departments.

Authors:  Camille Chenevier-Gobeaux; Mustapha Sebbane; Christophe Meune; Sophie Lefebvre; Anne-Marie Dupuy; Guillaume Lefèvre; Nicolas Peschanski; Patrick Ray
Journal:  BMJ Open       Date:  2019-06-16       Impact factor: 2.692

6.  Performance of Copeptin for Early Diagnosis of Acute Myocardial Infarction in an Emergency Department Setting.

Authors:  Ji Hun Jeong; Yiel Hea Seo; Jeong Yeal Ahn; Kyung Hee Kim; Ja Young Seo; Ka Yeong Chun; Yong Su Lim; Pil Whan Park
Journal:  Ann Lab Med       Date:  2020-01       Impact factor: 3.464

Review 7.  Past, Present, and Future of Blood Biomarkers for the Diagnosis of Acute Myocardial Infarction-Promises and Challenges.

Authors:  Ioan Tilea; Andreea Varga; Razvan Constantin Serban
Journal:  Diagnostics (Basel)       Date:  2021-05-15

8.  Initial Phase NT-proBNP, but Not Copeptin and High-Sensitivity Cardiac Troponin-T Yielded Diagnostic and Prognostic Information in Addition to Clinical Assessment of Out-of-Hospital Cardiac Arrest Patients With Documented Ventricular Fibrillation.

Authors:  Reidun Aarsetøy; Hildegunn Aarsetøy; Tor-Arne Hagve; Heidi Strand; Harry Staines; Dennis W T Nilsen
Journal:  Front Cardiovasc Med       Date:  2018-06-07

9.  N-terminal pro-B-type natriuretic peptide as a prognostic indicator for 30-day mortality following out-of-hospital cardiac arrest: a prospective observational study.

Authors:  Reidun Aarsetøy; Torbjørn Omland; Helge Røsjø; Heidi Strand; Thomas Lindner; Hildegunn Aarsetøy; Harry Staines; Dennis W T Nilsen
Journal:  BMC Cardiovasc Disord       Date:  2020-08-24       Impact factor: 2.298

Review 10.  Performance of Copeptin for Early Diagnosis of Acute Coronary Syndromes: A Systematic Review and Meta-Analysis of 14,139 Patients.

Authors:  Lukasz Szarpak; Marcin Lapinski; Aleksandra Gasecka; Michal Pruc; Wiktoria L Drela; Mariusz Koda; Andrea Denegri; Frank W Peacock; Miłosz J Jaguszewski; Krzysztof J Filipiak
Journal:  J Cardiovasc Dev Dis       Date:  2021-12-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.